Kaival Brands Innovations Group, Inc. 10-K

Item 8. Financial Statements and Supplementary Data. KAIVAL BRANDS INNOVATIONS GROUP, INC. CONSOLIDATED FINANCIAL STATEMENTS INDEX TO FINANCIAL STATEMENTS Pages Report of Independent Registered Public Accounting Firm (PCAOB ID: 206 ) F-2 Consolidated Balance Sheets F-3 Consolidated Statements of Operations F-4 Consolidated Statements of Changes in Stockholders’ Equity F-5 Consolidated Statements of Cash Flows F-6 Notes to Consolidated Financial Statements F-7 F- 1 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Shareholders and Board of Directors of Kaival Brands Innovations Group, Inc Opinion on the Financial Statements We have audited the accompanying consolidated balance sheet of Kaival Brands Innovations Group, Inc and its subsidiaries (collectively, the “Company”) as of October 31, 2025 and 2024, and the related consolidated statements of operations, changes in stockholders’ equity, and cash flows for the years then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of October 31, 2025 and 2024, and the results of their operations and their cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America. Going Concern Matter The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the Company has suffered recurring losses and negative cash flows from operations which raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 3. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Basis for Opinion These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. /s/ MaloneBailey, LLP www.malonebailey.com We have served as the Company's auditor since 2018. Houston, Texas January 28, 2026 F- 2 Kaival Brands Innovations Group, Inc. Consolidated Balance Sheets October 31, 2025 October 31, 2024 ASSETS CURRENT ASSETS Cash $ 534,406 $ 3,902,300 Accounts receivable, net 120,000 263,571 Prepaid expenses 14,850 344,312 Total current assets 669,256 4,510,183 Fixed assets, net — 2,146 Intangible assets, net — 10,681,911 Right of use asset - operating lease — 810,036 TOTAL ASSETS $ 669,256 $ 16,004,276 LIABILITIES AND STOCKHOLDERS’ EQUITY CURRENT LIABILITIES Accounts payable $ 349,289 $ 57,496 Accounts payable - related party 50,000 131,683 Loans payable, net — 207,616 Accrued expenses 170,000 925,601 Operating lease obligation - short term — 203,937 Total current liabilities 569,289 1,526,333 LONG TERM LIABILITIES Operating lease obligation, net of current portion — 662,271 TOTAL LIABILITIES 569,289 2,188,604 Commitments and Contingencies (Note 10) STOCKHOLDERS’ EQUITY Preferred stock; 5,000,000 shares authorized Series A Convertible Preferred stock ($ 0.001 par value, 3,000,000 shares authorized, none issued and outstanding as of October 31, 2025 and October 31, 2024) — — Series B Convertible Preferred stock ($ 0.001 par value, 900,000 shares authorized, 900,000 issued and outstanding as of October 31, 2025 and October 31, 2024) 900 900 Common stock ($.001 par value, 1,000,000,000 shares authorized, 11,593,402 and 8,517,302 shares issued and outstanding as of October 31, 2025 and October 31, 2024, respectively) 11,593 8,517 Additional paid-in capital 54,180,589 51,269,485 Accumulated deficit ( 54,093,115 ) ( 37,463,230 ) TOTAL STOCKHOLDERS’ EQUITY 99,967 13,815,672 TOTAL LIABILITIES & STOCKHOLDERS’ EQUITY $ 669,256 $ 16,004,276 The accompanying notes are an integral part of these consolidated financial statements. F- 3 Kaival Brands Innovations Group, Inc. Consolidated Statements of Operations For the Years Ended October 31, 2025 2024 Revenues Revenues, net $ 46,755 $ 5,882,597 Revenues - related party — 5,950 Royalty revenue 437,906 1,040,759 Excise tax on products — ( 42,641 ) Total revenues, net 484,661 6,886,665 Cost of revenue Cost of revenue - related party — 4,281,171 Total cost of revenue — 4,281,171 Gross profit 484,661 2,605,494 Operating expenses Advertising and promotion — 686,292 General and administrative expenses 7,286,991 7,628,050 Gain on termination of operating lease ( 59,823 ) — Loss on disposal of furniture and equipment 1,798 — Loss on impairment of intangible assets 9,895,503 — Total operating expenses 17,124,469 8,314,342 Other expense Loss on extinguishment of debt — ( 98,432 ) Loss on settlement of payables — ( 142,786 ) Interest expense, net ( 9,019 ) ( 729,558 ) Total other expense ( 9,019 ) ( 970,776 ) Loss before income taxes provision ( 16,648,827 ) ( 6,679,624 ) Benefit from (provision for) income taxes 18,942 ( 19,658 ) Net loss $ ( 16,629,885 ) $ ( 6,699,282 ) Preferred stock dividend ( 22,500 ) ( 270,000 ) Net loss attributable to common shareholders $ ( 16,652,385 ) $ ( 6,969,282 ) Net loss per common share - basic and diluted $ ( 1.51 ) $ ( 1.62 ) Weighted average number of common shares outstanding - basic and diluted 11,032,569 4,313,900 The accompanying notes are an integral part of these consolidated financial statements. F- 4 Kaival Brands Innovations Group, Inc. Consolidated Statements of Changes in Stockholders’ Equity For the years ended October 31, 2025, and 2024 Convertible Preferred Shares (Series B) Par Value Convertible Preferred Shares (Series B) Common Shares Par Value Common Shares Additional Paid-in Capital Accumulated Deficit Total Balances, October 31, 2023 900,000 $ 900 2,793,386 $ 2,793 $ 44,317,266 $ ( 30,763,948 ) $ 13,557,011 Rounding shares issued for reverse split — — 52,949 53 ( 53 ) — — Common shares issued for services — — 16,667 17 61,983 — 62,000 Issuance of common shares, warrants, and pre-funded warrants, net of issuance costs — — 1,746,500 1,747 5,250,980 — 5,252,727 Exercises of pre-funded warrants — — 2,174,456 2,174 ( 724 ) — 1,450 Exercises of warrants — — 333,200 333 385,413 — 385,746 Common shares issued to settle related party accounts payable — — 1,400,144 1,400 1,416,386 — 1,417,786 Preferred stock dividend — — — — ( 270,000 ) — ( 270,000 ) Stock option expense, net of forfeitures — — — — 108,234 — 108,234 Net loss — — — — — ( 6,699,282 ) ( 6,699,282 ) Balances, October 31, 2024 900,000 $ 900 8,517,302 $ 8,517 $ 51,269,485 $ ( 37,463,230 ) $ 13,815,672 Common shares issued for services — — 3,025,000 3,025 2,870,725 — 2,873,750 Preferred stock dividend — — — — ( 22,500 ) — ( 22,500 ) Issuance of common shares — — 51,100 51 24,242 — 24,293 Stock option expense — — — — 38,637 — 38,637 Net loss — — — — — ( 16,629,885 ) ( 16,629,885 ) Balances, October 31, 2025 900,000 $ 900 11,593,402 $ 11,593 $ 54,180,589 $ ( 54,093,115 ) $ 99,967 The accompanying notes are an integral part of these consolidated financial statements. F- 5 Kaival Brands Innovations Group, Inc. Consolidated Statements of Cash Flows For the Year Ended For the Year Ended October 31, 2025 October 31, 2024 CASH FLOWS FROM OPERATING ACTIVITIES Net loss $ ( 16,629,885 ) $ ( 6,699,282 ) Adjustments to reconcile net loss to net cash used in operating activities: Stock based compensation 2,873,750 62,000 Stock options expense 38,637 108,234 Depreciation and amortization 786,756 787,094 Make-whole provision 39,283 — Amortization of debt discount 6,781 214,095 Loss on extinguishment of debt — 98,432 Gain on termination of operating lease ( 59,823 ) — Loss on disposal of furniture and equipment 1,798 — Loss on impairment on intangible assets 9,895,503 — Bad debt expense — 27,995 ROU operating lease expense 102,410 198,392 Write-off of inventory — 61,927 Loss on settlement of payables — 142,786 Changes in current assets and liabilities: Accounts receivable 143,571 1,577,710 Prepaid expenses 329,462 561,837 Inventory — 4,009,897 Accounts payable 252,509 ( 316,836 ) Accounts payable - related party ( 81,683 ) ( 1,068,134 ) Accrued expenses ( 373,101 ) 138,194 Customer refunds due — ( 392,406 ) Operating lease obligations ( 98,758 ) ( 184,567 ) Net cash used in operating activities ( 2,772,790 ) ( 672,632 ) CASH FLOWS FROM INVESTING ACTIVITIES Net cash used in investing activities — — CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from loans payable — 1,106,731 Payments on loans payable ( 214,397 ) ( 2,486,594 ) Payments on loans payable - related party — ( 218,787 ) Proceeds from the issuance of common stock, warrants, and pre-funded warrants 24,293 5,997,720 Payments for issuance costs — ( 744,993 ) Proceeds from exercises of pre-funded warrants — 1,450 Proceeds from exercises of warrants — 385,746 Payments on preferred dividends ( 405,000 ) — Net cash (used in) provided by financing activities ( 595,104 ) 4,041,273 Net change in cash ( 3,367,894 ) 3,368,641 Beginning cash balance 3,902,300 533,659 Ending cash balance $ 534,406 $ 3,902,300 SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: Interest paid $ 9,019 $ 562,402 Income taxes paid $ — $ — NON-CASH TRANSACTIONS Preferred stock dividend $ 22,500 $ 270,000 Cashless exercise of pre-funded warrants $ — $ 724 Insurance financed by third party $ — $ 475,481 Franchise fees paid by related party $ — $ 218,787 Common shares issued to settle related party accounts payable $ — $ 1,417,786 The accompanying notes are an integral part of these consolidated financial statements. F- 6 KAIVAL BRANDS INNOVATIONS GROUP, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS Note 1 – Organization and Description of Business Kaival Brands Innovations Group, Inc. (the “Company,” the “Registrant,” “we,” “us,” or “our”), formerly known as Quick Start Holdings, Inc., was incorporated on September 4, 2018, in the State of Delaware. Description of Business On March 9, 2020, the Company entered into an exclusive distribution agreement (the “Distribution Agreement”) of certain electronic nicotine delivery systems (“ENDS”) and related components (the “Products”) with Bidi Vapor, LLC, a Florida limited liability company (“Bidi”). The Distribution Agreement was amended and restated on May 21, 2020, again on April 20, 2021, again on June 10, 2022 , and again on November 17, 2022 (collectively the “A&R Distribution Agreement”), in order to clarify some of the provisions and memorialize the Company’s current business relationship with Bidi. Pursuant to the A&R Distribution Agreement, Bidi granted the Company an exclusive worldwide right to distribute the Products for sale and resale to non-retail level customers. The Products consist primarily of the “Bidi Stick.” On August 31, 2020, the Company formed Kaival Labs, Inc., a Delaware corporation (herein referred to as “Kaival Labs”), as a wholly owned subsidiary of the Company, for the purpose of developing Company-branded and white-label products and services. The Company has not yet launched any Kaival-branded product, nor has it begun to provide white label wholesale solutions for other product manufacturers. On March 11, 2022, the Company formed Kaival Brands International, LLC, a Delaware limited liability company (herein referred to as “KBI”), as a wholly owned subsidiary of the Company, for the purpose of entering into an international licensing agreement with Philip Morris Products S.A. (“PMPSA”), a wholly owned affiliate of Philip Morris International Inc. (“PMI”). On June 13, 2022, the Company’s wholly owned subsidiary, KBI, entered into the PMI License Agreement with PMPSA, a wholly owned affiliate of PMI, for the development and distribution of ENDS products in certain markets outside of the United States, subject to market (or regulatory) assessment. The PMI License Agreement grants to PMPSA a license of certain intellectual property rights relating to Bidi’s ENDS device, known as the BIDI® Stick in the United States, as well as potentially newly developed devices, to permit PMPSA to manufacture, promote, sell, and distribute such ENDS device and newly developed devices, in international markets, outside of the United States. Product Offerings Pursuant to the A&R Distribution Agreement, the Company sells and resells electronic nicotine delivery systems, which it may refer to herein as “ENDS Products”, or “e-cigarettes”, to non-retail level customers. The sole Product the Company resells is the “BIDI ® Stick,” a disposable, tamper-resistant ENDS product that comes in a variety of flavor options for adult cigarette smokers. The Company does not manufacture any of the Products it resells. The BIDI ® Stick is manufactured by Bidi, who uses a contract manufacturer in China. Pursuant to the terms of the A&R Distribution Agreement, Bidi provides the Company with all branding, logos, and marketing materials to be utilized by the Company in connection with its marketing and promotion of the Products. Currently, the Company no longer sells BIDI ® Sticks. International Trade Commission (ITC) claims against the Company On June 11, 2024, the RJ Reynolds Entities filed the ITC Complaint. The ITC Complaint requests the ITC grant: (a) temporary and permanent limited exclusion orders pursuant to Section 337(e) of the Tariff Act of 1930, as amended, which would prohibit the importation of the Bidi Stick in the United States; and (b) issue temporary and permanent cease and desist orders pursuant to 337(f) of the Tariff Act of 1930, as amended, which would prohibit the sale and distribution of the Bidi Stick in the United States. No damages are recoverable in the proceedings before the ITC. If the Company or Bidi is prohibited from importing the Bidi Stick, then the Company’s business, operations, financial results, and reputation would be significantly adversely impacted. F- 7 As a result of the ITC Complaint and other factors, the Company does not expect any revenue from the sale of Bidi Sticks in the foreseeable future. The Company’s primary source of revenue is from KBI from royalties from PMI under the PMI License Agreement. Impact of the FDA PMTA Decision and Subsequent Court Actions In September 2021, in connection with the Bidi’s Premarket Tobacco Product Application (“PMTA”) process, the U.S. Food and Drug Administration’s (“FDA”) effectively “banned” flavored ENDS by denying nearly all then-pending PMTAs for such products. Following the issuance of Marketing Denial Orders (“MDO”), manufacturers are required to stop selling non-tobacco flavored ENDS products. Bidi, along with nearly every other company in the ENDS industry, received a MDO for its non-tobacco flavored ENDS products. With respect to Bidi, the MDO covered all non-tobacco flavored BIDI® Sticks, including its Arctic (menthol) BIDI® Stick. As a result, beginning in September 2021, Bidi pursued multiple avenues to challenge the MDO. First, on September 21, 2021, separate from the judicial appeal of the MDO in its entirety, Bidi filed a 21 C.F.R. § 10.75 internal FDA supervisory review request specifically of the decision to include the Arctic (menthol) BIDI® Stick in the MDO. In May 2022, the FDA issued a determination that it views the Arctic BIDI® Stick as a non-tobacco flavored ENDS product, and not strictly a menthol flavored product. On September 29, 2021, Bidi petitioned the U.S. Court of Appeals for the Eleventh Circuit (the “11 th Circuit”) to review the FDA’s denial of the comprehensive PMTAs for its non-tobacco flavored BIDI® Stick ENDS, arguing that it was arbitrary and capricious under the Administrative Procedure Act (“APA”), as well as ultra vires, for the FDA not to conduct any scientific review of Bidi’s comprehensive applications, as required by the Tobacco Control Act (“TCA”), to determine whether the BIDI® Sticks are “appropriate for the protection of the public health”. Bidi further argued that the FDA violated due process and the APA by failing to provide fair notice of the FDA’s new requirement for ENDS companies to conduct long-term comparative smoking cessation studies for their flavored products, and that the FDA should have gone through the notice and comment rulemaking process for this requirement. On October 14, 2021, Bidi requested that the FDA re-review the MDO and reconsider its position that Bidi did not include certain scientific data in its applications sufficient to allow the PMTAs to proceed to scientific review. In light of this request, on October 22, 2021, pursuant to 21 C.F.R. § 10.35(a), the FDA issued an administrative stay of Bidi’s MDO pending its re-review, permitting the Company to continue sales. Subsequently, the FDA decided not to rescind the MDO and lifted its administrative stay on December 17, 2021. Following the lifting of the FDA’s administrative stay, Bidi filed a renewed motion to stay the MDO with the 11 th Circuit. On February 1, 2022, the appellate court granted Bidi’s motion to stay (i.e., put on hold) the MDO, again allowing the Company to continue sales pending the litigation on the merits. On August 23, 2022, the U.S. Court of Appeals for the Eleventh Circuit set aside the MDO issued to the non-tobacco flavored BIDI® Sticks and remanded Bidi’s back to the FDA for further review. Specifically, the Court held that the MDO was “arbitrary and capricious” in violation of the Administrative Procedure Act (“APA”) because FDA failed to consider the relevant evidence before it, specifically Bidi’s aggressive and comprehensive marketing and sales-access-restrictions plans designed to prevent youth appeal and access. The FDA did not appeal to the 11 th Circuit’s decision. The FDA had until October 7, 2022 (45 days from the August 23, 2022, decision) to either request a panel rehearing or a rehearing “en banc” (a review by the entire 11 th Circuit, not just the 3-judge panel that issued the decision), and until November 21, 2022 (90 days after the decision) to seek review of the decision by the U.S. Supreme Court. No request for a rehearing was filed, and no petition for a writ of certiorari was made to the Supreme Court. On July 29, 2024, Bidi received a Recission of Marketing Denial letter from FDA formally rescinding the MDO for the non-tobacco flavored BIDI® Stick PMTAs and putting those applications back into the review process. On November 4, 2025, FDA issued a MDO for the PMTA for the non-tobacco flavored Bidi Sticks. FDA’s basis for this MDO is that Bidi Vapor’s PMTAs for non-tobacco flavored BIDI Stick did not include sufficient, robust evidence showing that marketing the flavored products would be “appropriate for the protection of the public health” (APPH)—i.e., that adult-smoker benefits (complete switching or significant cigarette reduction) would be large enough to outweigh the well-established youth-appeal and youth-initiation risks of flavored ENDS. In particular, FDA said the submission lacked the kind of comparative evidence (e.g., RCT/longitudinal cohort comparing flavored vs tobacco-flavored ENDS) needed to demonstrate an added adult benefit. FDA therefore concluded the applications were insufficient and stopped further scientific review of other sections. Accordingly, at this time, the non-tobacco flavored BIDI® Stick is considered an adulterated tobacco product, the continued marketing and distribution of which is prohibited. F- 8 Separately, on or about May 13, 2022, the FDA placed the tobacco-flavored Classic BIDI® Stick into the final Phase III scientific review. In March 2023, FDA issued a deficiency letter regarding the Classic BIDI® Stick PMTA, to which Bidi submitted in June 2023. Subsequently, on January 22, 2024, FDA issued a MDO for the Classic BIDI® Stick. On January 26, 2024, Bidi filed a petition for review of the MDO with the 11 th Circuit Court of Appeals, followed by a motion to stay the MDO. Bidi is arguing, among other things, that the MDO was arbitrary and capricious in violation of the Administrative Procedure Act. On February 2, 2024, Bidi filed a Time Sensitive Motion for a Stay Pending Review, which the court denied on February 18, 2024. Briefing on the merits proceeded, with Bidi filing the opening merits brief on April 15, 2024. FDA filed its response brief on June 7, 2024, and Bidi filed its reply brief on July 29, 2024. Oral arguments were held before a three-judge panel on the 11 th Circuit on April 2, 2025. The Court issued a decision on April 24, 2025, upholding FDA’s denial order. Accordingly, at this time, the Classic BIDI® Stick is considered an adulterated tobacco product, the continued marketing and distribution of which is prohibited. Risks and Uncertainties The FDA has indicated that it is prioritizing enforcement of unauthorized ENDS against companies (1) that never submitted PMTAs, (2) whose PMTAs have been refused acceptance or filing by the FDA, (3) whose PMTAs remain subject to MDOs, and (4) that are continuing to market unauthorized synthetic nicotine products after the July 13, 2022, cutoff. Due to the MDOs Bidi is no longer marketing the Classic BIDI® Stick or the non-tobacco flavored BIDI® Sticks. Merger and Share Exchange Agreement On September 23, 2024, the Company agreed with Delta Corp Holdings Limited, a company incorporated in England and Wales (“Delta”) to effect a business combination between the Company and Delta by entering into a Merger and Share Exchange Agreement (the “Merger Agreement”) among the Company, Delta, Delta Corp Holdings Limited, a Cayman Islands exempted company (“Pubco”), KAVL Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Pubco (“Merger Sub”), and the shareholders of Delta. On September 11, 2025, the Company and Delta entered into a Business Combination Termination and Release Agreement (the “Termination Agreement”) pursuant to Section 10.1(a) of the Merger Agreement (the “Merger Agreement’) among the Company, Delta, Pubco, KAVL Merger Sub Inc. and Delta Corp Cayman Limited. Pursuant to the Termination Agreement, the Company and Delta mutually terminated the Merger Agreement and all agreements between the parties that are ancillary thereto and Delta waived any and all claims against the other party that in any way directly and/or indirectly arise out of, are based upon, or are in connection with the Merger Agreement and any agreements ancillary thereto. Note 2 – Basis of Presentation and Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the financial statements of the Company’s wholly-owned subsidiaries, Kaival Labs and KBI. Intercompany transactions are eliminated. Basis of Presentation This summary of significant accounting policies is presented to assist in understanding the Company’s consolidated financial statements. These accounting policies conform to accounting principles, generally accepted in the United States of America (“GAAP”) and have been consistently applied in the preparation of the consolidated financial statements. F- 9 Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In the opinion of management, all adjustments necessary in order to make the financial statements not misleading have been included. Actual results could differ from those estimates. Cash The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. There were no cash equivalents as of October 31, 2025, and October 31, 2024. The Federal Deposit Insurance Corporation (“FDIC”) insures deposits according to the ownership category in which the funds are insured and how the accounts are titled. The standard deposit insurance coverage limit is $ 250,000 per depositor, per FDIC-insured bank, per ownership category. The Company had uninsured cash of $ 284,406 and $ 3,652,300 as of October 31, 2025, and October 31, 2024, respectively. Advertising and Promotion All advertising, promotion and marketing expenses, including commissions, are expensed when incurred. Accounts Receivable and Reserve for Credit Losses Accounts receivable pertains to contracts with customers who are granted credit by the Company in the ordinary course of business and are recorded at the invoiced amount. Accounts receivable does not bear interest. Accounts receivable presented on the consolidated balance sheets are adjusted for any write-offs and net of allowance for credit losses. The Company’s reserve for credit losses is developed by using relevant available information including historical collection and loss experience, current economic conditions, prevailing economic conditions, supportable forecasted economic conditions and evaluations of customer balances. Once a receivable is deemed uncollectible after collection efforts have been exhausted, it is written off against the reserve for credit losses. The Company closely monitors the credit quality of its customers and does not generally require collateral or other security on receivables. The reserve for credit losses is measured on a collective basis when similar risk characteristics exist. Based upon management’s assessment of the accounts receivable aging and the customers’ payment history, the Company has determined that no reserve for credit losses is required as of October 31, 2025 and October 31, 2024. On January 22, 2024, the FDA issued an MDO on Bidi Vapor’s “Classic” BIDI ® Stick PMTA, which was subsequently upheld by the 11 th Circuit Court of Appeals. The Company evaluated the impact of this MDO to the financial statements and recorded an estimated accrual for potential customer returns of the “Classic” products of zero and $ 46,775 as of October 31, 2025, and October 31, 2024, respectively, which is included in accrued expenses in the consolidated balance sheets. On November 4, 2025, FDA issued a MDO for the PMTA for the non-tobacco flavored Bidi Sticks. Credit Risk Financial instruments, which are potentially subject to concentrations of credit risk, consist primarily of purchases of inventories, accounts payable, accounts receivable, and revenue. The Company performs periodic credit evaluations of its customers and generally does not require collateral on trade receivables. Historically, the Company has not experienced significant credit losses. F- 10 Inventories All product inventory is purchased from a related party, Bidi. Inventories are stated at the lower of cost and net realizable value. Cost includes all costs of purchase and other costs incurred in bringing the inventories to their present location and condition. The Company determines cost based on the first-in, first-out (“FIFO”) method. Net realizable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale. During fiscal year 2025 and 2024, the Company recognized inventory write offs of zero 0 and $ 61,927 , respectively, related to short-coded Bidi sticks that were no longer saleable. On January 22, 2024, the FDA issued an MDO on Bidi Vapor’s tobacco-flavored “Classic” BIDI ® Stick PMTA. The appeal of that denial order before the 11 th Circuit Court of Appeals was unsuccessful. The Company evaluated the impact of this MDO to the financial statements and recognized a full reserve for all remaining “Classic” products on hand amounting to $ 313,654 as of October 31, 2024. The Company has zero inventory as of October 31, 2025. Leases The Company determines if a contract contains a lease at commencement of the arrangement based on whether it has the right to obtain substantially all of the economic benefits from the use of an identified asset and whether it has the right to direct the use of an identified asset in exchange for consideration, which relates to an asset which the Company does not own. Right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. The Company recognizes lease liabilities at the present value of the future lease payments and a corresponding ROU asset at the lease commencement date. The interest rate used to determine the present value of the future lease payments is the rate implicit in the lease unless that rate cannot be readily determined. When the interest rate implicit in the lease is not readily determinable, the interest rate used to determine the present value of the future lease payments is the Company’s Incremental Borrowing Rate (“IBR”). The IBR is a hypothetical rate based on the Company’s understanding of what its credit rating would be to borrow and resulting interest the Company would pay to borrow an amount equal to the lease payments in a similar economic environment over the lease term on a collateralized basis. Periods covered by the Company’s option to extend or terminate the lease are included in the lease term when it is reasonably certain that the Company will exercise its option to extend or not exercise its option to terminate, as applicable. Lease payments may be fixed or variable; however, only fixed payments or in-substance fixed payments are included in the Company’s lease liability calculation. Variable lease payments may include costs such as common area maintenance, utilities, real estate taxes or other costs. Variable lease payments are recognized in operating expenses in the period in which the obligations for those payments are incurred. The Company records rent expense for its operating lease, which has escalating rent payments, on a straight-line basis over the lease term. The Company does not have any financing leases. The Company made a policy election not to separate non-lease components from lease components for all its leases; therefore, it accounts for lease and non-lease components as a single lease component. The Company also elected the short-term lease recognition exemption for all leases that qualify, such that leases with a term of 12 months or less are not recognized on the balance sheet. During the fiscal year ended October 31, 2025, the Company determined that it would no longer be using the leased office space in its business operations and the lease liability was written off and recognized a net gain on termination of operating lease of $ 59,823 . Impairment of Long-Lived Assets The Company reviews its long-lived assets, which include definite-lived intangibles, long-lived fixed assets and lease right-of-use assets, for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Factors that could trigger an impairment review include significant under-performance relative to expected historical or projected future operating results, significant changes in the manner of the Company’s use of the acquired assets or the strategy for the Company’s overall business or significant negative industry or economic trends. If this evaluation indicates that the value of the long-lived asset may be impaired, the Company makes an assessment of the recoverability of the net carrying value of the asset over its remaining useful life. If this assessment indicates that the long-lived asset is not recoverable, based on the estimated undiscounted future cash flows of the technology over the remaining useful life, the Company reduces the net carrying value of the related asset to fair value and may adjust the remaining useful life. An impairment analysis is subjective and assumptions regarding future growth rates and operating expense levels can have a significant impact on the expected future cash flows and impairment analysis. F- 11 The Company evaluated its intangible assets for impairment and recognized an impairment loss of $ 9,895,503 for the year ended October 31, 2025. No impairment loss of long-lived assets was identified for the year ended October 31, 2024. Revenue Recognition The Company recognizes revenue in accordance with ASC Topic 606, “Revenue from Contracts with Customers” (“ASC 606”). The Company recognizes revenue when a customer obtains control of promised goods, in an amount that reflects the consideration that the Company expects to receive in exchange for the goods. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: (1) identify the contracts with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when or as the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods it transfers to the customer. Under ASC 606, disaggregated revenue from contracts with customers depicts the nature, amount, timing, and uncertainty of revenue and cash flows affected by economic factors. Products Revenue The Company generates products revenue from the sale of the Products (as defined above) to non-retail customers. The Company recognizes revenue at a point in time based on management’s evaluation of when performance obligations under the terms of a contract with the customer are satisfied and control of the Products has been transferred to the customer. In most situations, transfer of control is considered complete when the products have been shipped to the customer. The Company determined that a customer obtains control of the Product upon shipment when title of such product and risk of loss transfer to the customer. However, when the Company enters a consignment agreement with a new customer, once it ships and delivers the requested amount of ordered Products to its distribution center for its retail sales locations, the Company retains ownership of the delivered Products until they are delivered to the actual retail stores (as opposed to the Company’s consignment customer). The Company’s shipping and handling costs are fulfillment costs, and such amounts are classified as part of cost of sales. The Company offers credit sales arrangements to non-retail (or wholesale) customers and monitors the collectability of each credit sale routinely. Revenue is measured by the transaction price, which is defined as the amount of consideration expected to be received in exchange for providing goods to customers. The transaction price is adjusted for estimates of known or expected variable consideration, which includes refunds and returns as well as incentive offers and promotional discounts on current orders. Estimates for sales returns are based on, among other things, an assessment of historical trends, information from customers, and anticipated returns related to current sales activity. These estimates are established in the period of sale and reduce revenue in the period of the sale. Variable consideration related to incentive offers and promotional programs are recorded as a reduction to revenue based on amounts the Company expects to collect. Estimates are regularly updated, and the impact of any adjustments are recognized in the period the adjustments are identified. In many cases, key sales terms such as pricing and quantities ordered are established at the time an order is placed and incentives have very short-term durations. Amounts billed and due from customers are short term in nature and are classified as receivable since payments are unconditional and only the passage of time related to credit terms is required before payments are due. The Company does not grant payment financing terms greater than one year. Payments received in advance of revenue recognition are recorded as deferred revenue, as noted above. Royalty Revenue On June 13, 2022, KBI entered into the PMI License Agreement with PMPSA, effective as of May 13, 2022 (the “PMI Commencement Date”). Pursuant to the PMI License Agreement, KBI granted PMPSA an exclusive irrevocable license to use its technology, documentation, and intellectual property to make, distribute, and sell disposable nicotine e-cigarettes Products based on the intellectual property in certain international markets set forth in the PMI License Agreement (the “PMI Markets”). The Company has the exclusive international distribution rights to the Products and, F- 12 in order to allow KBI to fulfill its obligations set forth in the PMI License Agreement, has contributed the international distribution rights for the PMI Markets to KBI as set forth in a Capital Contribution Agreement, dated June 10, 2022. The sublicense granted to PMPSA is exclusive in the PMI Markets and neither KBI nor any of its affiliates can sell, promote, use, or distribute any competing products in the PMI Markets for the duration of the term of the PMI License Agreement and any Sell-Out Period (as defined in the PMI License Agreement). PMSPA will be responsible for any regulatory filings necessary to sell the Products in the PMI Markets. Both KBI and PMPSA agree to work together in the registration and maintenance of the Intellectual Property, but KBI will bear all cost and expense to implement the registration strategy. Finally, PMPSA has agreed to potential future development services with KBI in the PMI Markets and has been granted certain rights with respect to potential future products. The initial term of the PMI License Agreement is five (5) years and automatically renews for an additional five-year period unless PMPSA has failed to meet the agreed upon minimum key performance indicators set forth in the PMI License Agreement, in which case the PMI License Agreement will automatically terminate at the end of the initial license term. In consideration for the grant of the licensed rights, PMPSA agreed to pay to KBI a royalty equal to a percentage of the base price of the first sale of each unit of Product manufactured. In addition, before the launch of the first product in a market and each anniversary of such launch, PMPSA agrees to pre-pay to KBI a guaranteed minimum royalty based on the estimated royalties payable by PMPSA to KBI in relation to all markets in the twelve (12)-month period following the first launch or each successive anniversary of the first launch, subject to an aggregate maximum guaranteed royalty payment for all markets for each applicable twelve (12)-month period. PMPSA may require modification of certain products to be sold under the PMI Licensing Agreement to be modified for a PMI Market. Pursuant to the PMI Licensing Agreement, PMPSA has absolute discretion over sales, marketing, product branding and packaging pertaining to sales in the PMI Markets, as well as the right to select the specific PMI Markets in which to launch commercialization and determine what product types are to be promoted in each market, subject to sales and marketing plans and annual business plans set by PMPSA and certain expansion criteria agreed between PMPSA and KBI. Royalty revenue earned from the PMI License Agreement is recognized in the period the sales of the Product manufactured occurs. The PMI License Agreement contains customary representations, warranties, covenants, and indemnification provisions; however, KBI’s liability under the PMI License Agreement is capped at the greater of: (i) Ten Million Dollars ($ 10,000,000 ); or (ii) an amount equal to the total of the royalties due to KBI (but not yet paid) plus the royalties (including the guaranteed royalty payment) paid to KBI pursuant to the PMI License Agreement during the immediately preceding twelve (12) consecutive months, provided that such amount shall not exceed Thirty Million Dollars ($ 30,000,000 ). On June 10, 2022, Bidi entered into a License Agreement (the “KBI License Agreement”) with KBI, pursuant to which KBI has the exclusive irrevocable license to use Bidi’s licensed intellectual property to the extent necessary for KBI to fulfill its obligations set forth in the PMI Licensing Agreement. Such irrevocable license includes: (i) the right of KBI to grant sub-licenses to PMPSA under the PMI License Agreement for the express purposes set forth in the PMI License Agreement, but for no other purpose; (ii) the right of KBI to grant to PMPSA the right to grant sub-sub-licenses in the manner set forth in the PMI License Agreement, but for no other purpose; and (iii) certain branding rights to the extent (but only to the extent) necessary to permit KBI to perform its obligations to PMPSA as set forth in the PMI License Agreement. On August 12, 2023, the Company executed and entered into a Deed of Amendment No. 1 (the “PMI License Amendment”) with PMPSA, Bidi and KBI. Pursuant to the PMI License Amendment (which has an effective date of June 30, 2023), the following material changes have been made to the PMI License Agreement: 1. Royalty Rate. The royalty paid by PMPSA to KBI will no longer be based on sales price of the Product being sold, but rather on the volume of liquid contained within Product being sold. The royalty will be on a sliding scale of between $0.08 to $0.16 per sale based on the volume of liquid contained in the Product, increasing to between $0.10 to $0.20 per sale upon meeting certain sales milestones. For purposes of determining aggregate sales threshold, all sales undertaken since commencement of the PMI Licensing Agreement will be counted. 2. Elimination of Certain Potential Royalty Adjustments. Certain potential adjustments to the royalties receivable by KBI as provided for in the PMI License Agreement have been eliminated. F- 13 3. Guaranteed Royalty. The guaranteed royalty payment owed to KBI under the PMI License Agreement has been eliminated. Instead, royalties will be paid on a quarterly basis going-forward based on actual sales. Any unpaid guaranteed royalty has been cancelled. 4. Insurance Tail Requirements. KBI’s requirement to keep certain tail insurance after the expiration or termination of the PMI Licensing Agreement was reduced from 6 years to 2 years. 5. Markets. The identification of the PMI Markets that PMI may enter has been expanded to cover certain additional territories. 6. Net Reconciliation Payment to KBI. As a result of the changes to the PMI License Agreement described in paragraphs 1 through 3 above, the value of such changes was calculated and reconciled as of the date of commencement of the PMI Licensing Agreement through June 30, 2023. The KBI License Agreement provides that KBI shall pay Bidi license fees equivalent to 50% of the adjusted earned royalty payments, after any offsets due to jointly agreed costs such general and administrative costs incurred for insurance. During the year ended October 31, 2025, the Company paid license fees of approximately $266,215 to Bidi. As of October 31, 2025 and 2024, $ 50,000 and 131,683 , respectively, of license fees are owed to Bidi. As of October 31, 2025, amounts receivable from PMPSA in connection with the PMI license agreement pertaining to royalties totaled $ 120,000 , of which $ 120,000 and $ 0 pertain to royalties and reimbursements of certain non-recurring engineering costs, respectively. As of October 31, 2024, amounts receivable from PMPSA in connection with the PMI license agreement pertaining to royalties totaled $ 263,367 , of which $ 263,367 and $ 0 pertain to royalties and reimbursements of certain non-recurring engineering costs, respectively Net Loss Per Share Basic net loss per share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period, without consideration of potential common stock equivalents. Diluted net loss per share is calculated by dividing net loss available to common stockholders by the weighted average number of common stock outstanding plus common share equivalents from conversion of dilutive stock options and warrants using the treasury method and preferred stock using the if-converted method, except when antidilutive. In the event of a net loss, the effects of all potentially dilutive shares are excluded from the diluted net loss per share calculation as their inclusion would be antidilutive. As of October 31, 2025, and 2024, there were 5,810,353 and 5,944,276 , respectively, units of common stock equivalents that consists of options and warrants units, as well as 357,120 shares issuable upon preferred stock conversions, that were excluded from the current and prior period diluted loss per share calculation as their effect is anti-dilutive. Concentration of Revenues and Accounts Receivable No revenue concentration from the sale of Products existed for the year ended October 31, 2025. For the year then ended October 31, 2024, (i) 21 % or $ 1,236,491 of the revenue from the sale of Products, solely consisting of the BIDI® Stick, was generated from QuikTrip Corporation, (ii) 12 % or $ 678,562 was generated from GPM Investments, LLC, and (iii) 11 % or $ 655,583 was generated from FAVS Business, LLC. On May 2, 2024, QuikTrip Corporation terminated its consignment arrangement with the Company. No accounts receivable concentration from the sale of Products existed as of October 31, 2025. QuikTrip Corporation with an outstanding balance of $ 205 accounted for 100% of the total accounts receivable from customers as of October 31, 2024. F- 14 Share-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments (share-based payments, referred to herein as “SBP”) based on the grant-date fair value of the award. That cost is recognized over the period during which a recipient is required to provide service in exchange for the SBP award—the requisite service period (vesting period). For SBP awards subject to performance conditions, compensation is not recognized until the performance condition is probable of occurrence. The grant-date fair value of share options is estimated using the Black-Scholes-Merton option-pricing model. There were no options granted during the fiscal twelve-month period ended October 31, 2025. The fair value of each option granted during the fiscal year then ended October 31, 2024, was estimated on the date of grant using the Black-Scholes-Merton option-pricing model with the weighted average assumptions in the following table: Schedule of weighted average assumptions As of October 31, 2024 Expected dividend yield 0 % Expected option term (years) 5.5 – 7 Expected volatility 214.72 - 225.52 % Risk-free interest rate 3.78 - 4.63 % The expected term of options granted represents the period of time that options granted are expected to be outstanding. The expected volatility was based on the volatility in the trading of the Company’s common stock. The risk-free interest rate used is based on the published U.S. Department of Treasury interest rates in effect at the time of stock option grant for zero coupon U.S. Treasury notes with maturities approximating each grant’s expected term. Forfeitures and cancellations are recorded as they occur. Income Tax Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due plus deferred taxes related primarily to differences between the recorded book basis and the tax basis of assets and liabilities for financial and income tax reporting. Deferred tax assets and liabilities represent the future tax return consequences of those differences, which will either be taxable or deductible when the assets and liabilities are recovered or settled. Deferred taxes are also recognized for operating losses that are available to offset future taxable income and tax credits that are available to offset future federal income taxes. The Company believes that its income tax filing positions and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material adverse effect on the Company’s financial condition, results of operations, or cash flow. The Company has Federal net operating loss (“NOL”) carryforwards, consisting of total deferred tax assets, totaling approximately $ 34.2 million and state NOL carryforwards, consisting of total deferred tax liabilities, totaling approximately $ 0.4 million. With the changes instituted by the CARES Act, the Federal NOLs have an indefinite life and will not expire. The Company’s federal and state tax returns for the 2022, 2023, and 2024 tax years generally remain subject to examination by U.S. and various state authorities. A valuation allowance is recorded to reduce the deferred tax asset if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax asset will not be realized. After consideration of all the evidence, both positive and negative, management has determined that a valuation allowance of $ 10.1 million for the year ended on October 31, 2025, and a valuation allowance of $ 8,703,742 for the year ended on October 31, 2024 were necessary to reduce the total net deferred tax asset to the amount that will more likely than not be realized pursuant to ASC 740 for those fiscal years. Fair Value of Financial Instruments The Company’s balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization. F- 15 ASC 820, Fair Value Measurements and Disclosures (“ASC 820”), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below: ● Level 1 – Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. ● Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means. ● Level 3 – Inputs that are both significant to the fair value measurement and unobservable. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of October 31, 2025 and 2024. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash, accounts receivable, accounts payable, accrued expenses and loans payable. As of October 31, 2025, and 2024, the Company did not have any financial assets or liabilities measured and recorded at fair value on a recurring basis. Segment Reporting In accordance with ASC 280, Segment Reporting , the Company has identified one reportable segment, which aligns with how the Chief Operating Decision Maker (“CODM”), consisting of the Company’s Chief Executive Officer, assesses financial performance and allocates resources across the Company’s operations. The measure of segment profit or loss is net loss as per the consolidated statements of operations and the measure of segment assets is total assets reported on the consolidated balance sheets. Recently Adopted Accounting Pronouncement In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,” which is intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The purpose of the amendment is to enable investors to better understand an entity’s overall performance and assess potential future cash flows. The Company adopted ASU 2023-07 in this Annual Report on Form 10-K and will adopt the interim disclosures in the first quarter of 2026. ASU 2023-07 was adopted retrospectively to all periods presented in the financial statements. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements. Recent Accounting Pronouncement – Not Yet Adopted In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-09, Income Taxes (Topic 740) - Improvements to Income Tax Disclosures (“ASU 2023-09”). ASU 2023-09 requires additional disclosures reconciling the rates of different categories of income tax (i.e. federal, state, foreign, etc.) and a disaggregation of taxes paid and refunded. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, and for interim periods in fiscal years beginning after December 15, 2025, although early adoption is permitted. The Company is currently evaluating the impact of adopting this standard on its income tax disclosures. F- 16 Note 3 – Going Concern The accompanying consolidated financial statements of the Company are prepared in accordance with U.S. GAAP applicable to a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business within one year after the date the consolidated financial statements are issued. In accordance with FASB, ASU No. 2014-15, Presentation of Financial Statements – Going Concern (Subtopic 205-40), the Company’s management evaluates whether there are conditions or events, considered in aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the accompanying consolidated financial statements are issued. The Company has incurred recurring losses and negative cash flows from operations for the years ended October 31, 2025 and 2024. The Company will need significant additional funds to satisfy its outstanding payables, fund its working capital, and fully implement its business plan. In addition, the Company’s ability to continue as a going concern is adversely affected by the FDA’s denial of Bidi’s PMTA for its non-tobacco flavored Bidi ® Stick as well as the Company’s inability to continue to sell the Bidi Stick given the patent infringement claim filed by RJ Reynolds. Likewise, in April 2025 the 11 th Circuit upheld FDA’s MDO for the Classic BIDI® Stick. Subsequently, on November 4, 2025, FDA issued a MDO for the PMTA for the non-tobacco flavored Bidi Sticks. All of these factors raise substantial doubt regarding the Company’s ability to continue as a going concern. The Company plans to continue developing strategies for similar or expanded operations for the Company’s business to help the Company’s ability to determine where its business will be viable going forward. Until such time, if ever, the Company can generate substantial product revenues, management plans to finance its cash needs through public or private equity offerings or debt financing. However, there is no assurance that the Company will be able to raise additional capital, generate revenues or achieve profitability due to the factors listed above as well as the regulation and public perception of ENDS products and the various other risks faced by the Company. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of these or other risks or uncertainties. Note 4 – Intangible Assets The Company’s intangible assets include patents and technology that were acquired pursuant to the GoFire Asset Purchase Agreement (“GoFire APA”). The cost and accumulated amortization and impairment of the intangible assets amounted to $ 11,795,975 and $ 11,795,975 as of October 31, 2025, respectively and $ 11,795,975 and $ 1,114,064 as of October 31, 2024, respectively. Amortizable patents and technology have a useful life of 15.0 years with a weighted average remaining useful life of 0 years and 13.7 years as of October 31, 2025 and October 31, 2024, respectively. The Company recognized an amortization expense of $ 786,408 and $ 786,398 for the years then ended October 31, 2025 and 2024, respectively. Amortization expense is included under general and administrative expenses in the consolidated statements of operations. As of October 31, 2025, as a result of the termination of the merger and share exchange agreement with Delta and the uncertainty in the Company’s ability to monetize and generate future cash flows from the GoFire patents, the Company recognized an impairment loss on the intangible assets of $ 9,895,503 . Note 5 – Loans Payable Insurance Loans On May 10, 2024, the Company obtained two insurance loans. The first loan is a nine-month loan from First Insurance Bank to finance the annual D&O insurance, with the principal amount of $ 381,077 and subject to an effective interest rate of 7.45 %. The second loan is a nine-month loan from IPFS Corporation to finance the annual D&O insurance, with the principal amount of $ 94,404 and subject to an effective interest rate of 11.15 %. As of October 31, 2025 and October 31, 2024, the outstanding balance of the insurance loans amounted to zero 0 and $ 207,616 , respectively. For the year ended October 31,2025, the Company recorded $ 6,781 for total amortization for insurance loans. F- 17 Loan Agreements On August 9, 2023, the Company entered into a Securities Purchase Agreement (the “SPA”) with AJB Capital Investments, LLC (“AJB”), pursuant to which the Company sold a Promissory Note in the principal amount of $650,000 (the “Note”) to AJB in a private transaction for a purchase price of $585,000 (giving effect to original issue discount of $65,000). The Note matured on February 8, 2024 (the “Maturity Date”) and had interest at the rate of 10% per annum. Interest was payable on a monthly basis beginning on the date one month following the date of issuance of the Note. Pursuant to the terms of the SPA, the Company paid a commitment fee to AJB in the form of 19,048 shares of Common Stock (the “Commitment Fee Shares”) with a relative fair value of $130,478 which was recognized as discount to the note. The debt discount and issuance costs were amortized over the term of the note. Amortization expense amounted to zero and $38,273 for the years ended October 31, 2025, and 2024, respectively. Under the SPA, the Company had the right to repurchase half of the Commitment Fee Shares if the Note was repaid in full prior to maturity. On December 1, 2023, the Company fully paid the loan balance in advance of the maturity date. In connection with the repayment of the Note, the Company agreed that AJB would be permitted to retain all of the Commitment Fee Shares. The Company recognized $ 98,432 as loss on extinguishment of debt for the year ended October 31, 2024. As of October 31, 2025 and October 31, 2024, the carrying value of the Note was zero. Note 6 – Leases The Company does not have financing leases and only have one operating lease for office space and inventory storage space with Just Pick, LLC (“Just Pick”), a related party that was owned and controlled by Nirajkumar Patel, the former Chief Executive Officer and Director of the Company (see Note 8). Certain of the Company’s leases, have and may in the future, include renewal options, which have been and might be in the future, included in the calculation of the lease liabilities and right of use assets when the Company is reasonably certain to exercise the option. Schedule of cash flow information related to leases October 31, 2025 October 31, 2024 Other Lease Information Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ ( 102,410 ) $ ( 198,392 ) As of October 31, 2025, the Company had no lease liability. As of October 31, 2025, the Company had no additional leases which had not yet commenced. On April 23, 2025, the Company received a letter of demand from Just Pick, LLC, noting that the Company was in breach of the lease as base rent and operating expenses have not been paid since January 8, 2025. On April 30, 2025, the Company responded and provided Just Pick, LLC with a termination notice. As of April 30, 2025, the Company determined that it would no longer be using the leased office space in its business and recorded a loss on the ROU assets of $ 707,626 , accordingly. In May 2025, the Company paid the total unpaid lease payments through May 2025 amounting to $ 78,217 . On January 7, 2026, the Company executed a settlement agreement with Just Pick where both parties agreed to no further payments remaining for the office lease liability. The lease liability was written off as of October 31, 2025 and the Company recognized a net gain of approximately $ 59,000 from the termination of the lease. F- 18 Note 7 – Stockholders’ Equity Series B Convertible Preferred Stock On May 30, 2023, the Company issued 900,000 shares of the Series B Preferred Stock as consideration for the acquisition of the GoFire Purchased Assets. The Series B Preferred Stock carries no voting rights except: (i) with respect to the ability of the holders of a majority of the then outstanding Series B Preferred Stock (the “Majority Holders”), to nominate a director to the Company’s board of directors, and (ii) that the vote of the Majority Holders is necessary for effecting any amendment to the Company’s Certificate of Incorporation or Certificate of Designation that affects the Series B Preferred Stock. The Series B Preferred Stock is redeemable at the option of the Company at a redemption price of $ 15 per share, subject to potential downward adjustments based on the trading price of the Common Stock. Subject to additional limitations in the GoFire APA, the Series B Preferred Stock holds seniority over the Common Stock and each other class of series of securities now existing or hereafter authorized with respect to dividend rights, the distribution of assets upon liquidation, and dissolution and redemption rights. Upon a liquidation and winding up of the Company, the holders of Series B Preferred Stock are entitled to a liquidation preference of $ 15 per share (the “Liquidation Preference”), though the redemption may be adjusted downward based on the trading price of the Common Stock at the time of liquidation. The holders of Series B Preferred Stock are entitled to receive a dividend equal to 2% of the Liquidation Preference, accruing from the Closing Date and payable on the eighteen-month anniversary of the Closing Date. Amounts payable in respect of the Series B Dividend shall begin to accrue on a daily basis, be cumulative from and including the Original Issue Date, whether or not the Corporation has funds legally available for such dividends or such dividends are declared, shall compound on each six month anniversary of the Original Issue Date and shall be payable in arrears on the 18-month anniversary of the Original Issue Date. No preemptive rights are granted to the holders of Series B Preferred Stock. The Majority Holders have the ability to cause a voluntary conversion of the Series B Preferred Stock into Common Stock at a conversion rate of 0.3968 shares of Common Stock per share of Series B Preferred Stock which may only occur on or after the following dates 18-month, 24 month, 36 month, 48 month, and 60 month anniversary of the original issuance date; and only up to 180,000 shares of Series B Preferred Stock on each of these dates. All shares of Series B Preferred Stock will automatically convert to Common Stock upon the occurrence of a Change of Control (as defined in the GoFire APA). On December 3, 2024, the Company paid accrued dividends of $ 405,000 to Series B shareholders. As of October 31, 2025, the Company had zero accrued dividend payable to Series B shareholders and no further dividends will be accrued or paid. Pursuant to the GoFire APA, the Company is required to use commercially reasonable efforts to register the APA Shares and Warrant Shares with the SEC for distribution to GoFire’s stockholders and/or public resale by such stockholders within 180 days of the Closing Date. In addition, if any Series B Preferred Stock remains outstanding nineteen (19) months after the Closing Date, the Company shall use commercially reasonable efforts to file with the SEC a subsequent registration statement registering the distribution to GoFire’s stockholders and/or public resale Series B Conversion Shares by such stockholders. If such subsequent registration statement is required, the Company will use its commercially reasonable efforts to obtain effectiveness of such subsequent registration statement within nineteen (19) months of the Closing Date, and if the Company does not so register the Series B Conversion Shares within nineteen (19) months of the Closing Date, the Company will issue to GoFire or its designee an additional ten percent (10%) of all of the Series B Conversion Shares underlying the then outstanding shares of Series B Preferred Stock. All of the securities issued as consideration for the Purchased Assets are subject to a lock-up agreement that terminates one hundred eighty (180) days from the Closing Date. As of October 31, 2025, the Company made an accrual for the additional ten percent (10%) of all of the Series B Conversion Shares of $ 39,283 . Reverse Stock Split On January 22, 2024, the Company filed a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to affect a 1-for-21 reverse stock split (the “2024 Reverse Stock Split”) of the shares of the Common Stock. The 2024 Reverse Stock Split was effective on January 25, 2024, on the Nasdaq Stock Market. No fractional shares were issued in connection with the 2024 Reverse Stock Split. Any fractional shares of the Company’s Common Stock that would have otherwise resulted from the 2024 Reverse Stock Split were rounded up to the nearest whole number. In connection with the 2024 Reverse Stock Split, F- 19 the Board approved appropriate and proportional adjustments to all outstanding securities or other rights convertible or exercisable into shares of the Common Stock, including, without limitation, all preferred stock, warrants, options, and other equity compensation rights. All historical share and per-share amounts reflected throughout these accompanying consolidated financial statements have been retroactively adjusted to reflect the 2024 Reverse Stock Split as if the split occurred as of the earliest period presented. The par value per share of the Common Stock was not affected by the 2024 Reverse Stock Split. Common Stock During the year ended October 31, 2025, the Company issued 3,025,000 fully vested shares of common stock, respectively, to directors, officers and an employee pursuant to grants under the Company’s Amended and Restated 2020 Stock and Incentive Compensation Plan. During the year ended October 31, 2025, the Company issued 51,100 shares of common stock through an ATM offering raising $ 24,293 and paid fees of $ 850 to Maxim for net proceeds of $ 23,443 . During the year ended October 31, 2024, the Company issued 1,746,500 shares of common stock in connection with the June 2024 Public Offering (see below). During the year ended October 31, 2024, the Company issued 2,174,456 shares of common stock from exercises of pre-funded warrants (see below). During the year ended October 31, 2024, the Company issued 52,949 shares of common stock for rounding of shares related to the Reverse Split. During the year ended October 31, 2024, the Company issued 16,667 shares of common stock to a FINRA member broker-dealer in connection with the termination of its relationship with such broker dealer. The fair value was $ 62,000 based on the closing price of the common stock on the termination date and recorded as stock-based compensation. During the year ended October 31, 2024, the Company issued 333,200 shares of common stock from exercises of warrants for total consideration of $ 385,746 . During the year ended October 31, 2024, the Company issued 1,400,144 shares of common stock to settle the related party payable to Bidi of $ 1,275,000 . The Company recognized a loss on the settlement of the payable of $ 142,786 . June 2024 Public Offering On June 21, 2024, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with the certain purchasers (the “Purchasers) for the purchase and sale of an aggregate of $5,393,250 of the Company’s securities consisting of 3,525,000 units (the “Units’). With respect to (i) 1,350,000 of the Units (the “Common Units”), each such Common Unit consisted of one share of the Company’s common stock, par value $0.001 per share (“Common Stock”) and one and one-half common warrants (“Common Warrants”) to purchase one and one-half shares of Common Stock and (ii) the other 2,175,000 Units (the “Pre-funded Units”), each such Pre-funded Unit consisted of a pre-funded warrant (“Pre-funded Warrant”) to purchase one share of Common Stock and one and one-half Common Warrants. Pursuant to the Purchase Agreement, the Common Units were sold at a purchase price of $1.53 per Unit and the Pre-funded Units were sold at a purchase price of $1.529 per Unit. The sale of the Units to the Purchasers closed on June 24, 2024 (the “Closing Date”). The Company also sold 396,500 Common Units to additional investors, who did not enter into the Purchase Agreement, under the same terms sold to Purchasers. The sale of securities by the Company pursuant to the Purchase Agreement combined with the concurrent sale of securities to additional investors is referred to herein as the “June 2024 Public Offering’. The aggregate gross proceeds to the Company from the June 2024 Public Offering were approximately $ 5,997,720 , before deducting placement agent fees and expenses and other transaction costs of $ 744,993 . Of the total gross proceeds, $ 2,672,145 and $ 3,325,575 were allocated to the common stock and the pre-funded warrants, respectively. See further Common Warrants and Pre-Funded Warrants details below. F- 20 Stock Options Summary of stock options information is as follows: Schedule of stock options information Average Aggregate Number Aggregate Exercise Price Exercise Price Range Exercise Price Outstanding, October 31, 2023 449,106 $ 14,081,408 $ 10.08 - 602.28 $ 31.36 Granted 104,693 529,899 2.81 - 11.76 5.06 Exercised — — — — Cancelled, forfeited, or expired ( 364,209 ) ( 7,763,571 ) 2.81 - 545.58 15.75 Outstanding, October 31, 2024 189,590 $ 6,847,736 $ 3.64 - 602.28 $ 36.12 Granted — — — — Exercised — — — — Cancelled, forfeited, or expired ( 133,923 ) ( 5,999,707 ) $ 15.33 - 602.28 44.80 Outstanding, October 31, 2025 55,667 $ 848,028 $ 3.64 - 59.85 $ 15.23 Exercisable, October 31, 2025 54,477 $ 828,314 $ 3.64 - 59.85 $ 15.20 During the years ended October 31, 2025, and 2024, the Company recognized $ 38,637 and $ 108,234 , respectively of stock option expense related to outstanding stock options. No options were granted during the twelve-months ended October 31, 2025. The weighted-average grant-date fair value of the options granted during the fiscal years ended October 31, 2024 was $ 5.03 . The total fair value of stock options that vested during the fiscal years ended October 31, 2025 and October 31, 2024 were $ 38,977 and $ 830,907 respectively. On October 31, 2025, the Company had $ 16,299 of unrecognized expenses related to options, which is expected to be recognized over a weighted-average period of approximately 1.68 years. The weighted average remaining contractual life is approximately 7.84 years for stock options outstanding as of October 31, 2025. The aggregate intrinsic value of these outstanding options as of October 31, 2025 was zero. Compensation expense related to performance-based options is recognized on a straight-line basis over the requisite service period, provided that it is probable that performance conditions will be achieved, with probability assessed on a quarterly basis and any changes in expectations recognized as an adjustment to earnings in the period of the change. Compensation cost is not recognized for service and performance-based awards that do not vest because service or performance conditions are not satisfied, and any previously recognized compensation cost is reversed. If vesting occurs prior to the end of the requisite service period, expense is accelerated and fully recognized through the vesting date. Warrants Warrant information as of the periods indicated is as follows: Schedule of warrant information Aggregate Average Aggregate Number Exercise Price Exercise Price Range Exercise Price Outstanding, October 31, 2023 242,548 $ 13,946,006 $ 12.39 - 126.00 $ 57.51 Granted 8,057,250 6,812,056 .001 - 1.16 0.85 Exercised ( 2,508,200 ) ( 387,921 ) .001 - 1.16 0.15 Cancelled, forfeited, or expired ( 36,912 ) ( 544,025 ) 12.39 - 15.33 14.74 Outstanding, October 31, 2024 5,754,686 $ 19,826,116 $ 1.16 - 126.00 $ 3.45 Granted — — — — Exercised — — — — Cancelled, forfeited, or expired — — — — Outstanding, October 31, 2025 5,754,686 $ 19,826,116 $ 1.16 - 126.00 $ 3.45 Exercisable, October 31, 2025 5,754,686 $ 19,826,116 $ 1.16 - 126.00 $ 3.45 The weighted average remaining contractual life is approximately 3.56 years for Common Stock warrants outstanding as of October 31, 2025. As of October 31, 2025, the intrinsic value of outstanding stock warrants was zero. F- 21 Pre-Funded Warrants The Company issued a pre-funded warrant to purchase an aggregate of 2,175,000 shares of Common Stock in connection with the June 2024 Public Offering. The Pre-funded Warrants were sold to Purchasers whose purchase of Common Units in the June 2024 Public Offering would have otherwise resulted in such Purchaser beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of the Company’s outstanding Common Stock. The exercise price of each Pre-funded Warrant is $ 0.001 per share. The Pre-funded Warrants are exercisable immediately and may be exercised at any time until all of the Pre-funded Warrants are exercised in full. Immediately after the Closing Date, the Purchasers of the Pre-funded Units exercised all of the 2,175,000 Pre-funded Warrants and purchased shares of common stock. The Company issued 2,174,456 shares of common stock from exercises of pre-funded warrants, consisting of 1,450,000 Pre-funded Warrants through cash exercise and 725,000 Pre-funded Warrants through cashless exercise. The Company received proceeds amounting to $ 1,450 from the cash exercise of the Pre-funded Warrants. As of October 31, 2024 and October 31, 2025, there were no Pre-Funded Warrants outstanding. Note 8 – Related-Party Transactions In March 2020, the Company commenced business operations as a result of becoming the exclusive distributor of certain ENDS and related components (the “Products”) manufactured by Bidi, a related party company that is also owned by Nirajkumar Patel, the former Chief Executive Officer and Director of the Company. On June 24, 2024, the Company obtained a short-term loan from Bidi, a related party company to finance the state and franchise tax fees. The principal amount was $218,787 and was not subject to interest. The entire principal balance of this loan shall be due and payable in full immediately upon receipt of funds by the Company pursuant to the June 2024 Public Offering noted above. This loan was fully paid on June 25, 2024 and has no remaining outstanding balance. Revenue and Accounts Receivable During the fiscal years ended October 31, 2025 and October 31, 2024, the Company recognized revenue of zero 0 and $ 5,950 from one company owned by Nirajkumar Patel, the former Chief Executive Officer and former Director of the Company, and/or his wife. There was no accounts receivable balance for these transactions as of October 31, 2025 and October 31, 2024. Purchases and Accounts Payable There were no purchases of inventory from Bidi for the year ended October 31, 2025 and no amounts owed to Bidi for inventory purchases as of October 31, 2025. During the fiscal year ended October 31, 2024, 100% of the inventories of Products, consisting solely of the BIDI® Stick, were purchased from Bidi, a related party controlled by Nirajkumar Patel, the former Chief Executive Officer and Director of the Company, in the amount of $ 250,560 , As of October 31, 2024, the Company had $ 0 in accounts payable to Bidi from inventory purchases. The KBI License agreement provides that KBI shall pay Bidi license fees equivalent to 50% of the adjusted earned royalty payments, after any offsets due to jointly agreed costs such development costs incurred for entry to specific international markets. During the years ended October 31, 2025 and October 31, 2024, the Company paid license fees of approximately $ 266,215 and $ 220,000 to Bidi, respectively. As of October 31, 2024, the Company has a payable to Bidi of $ 131,683 related to the PMI License Agreement of which $ 108,215 was paid in December 2024. As of October 31, 2025, the Company has a payable of approximately $ 50,000 related to the PMI License Agreement of which $ 37,500 was paid in January 2026. Leased Office Space and Storage Space On June 10, 2022, the Company entered into a Lease Agreement with Just Pick, owned and controlled by Nirajkumar Patel, the former Chief Executive Officer and Director of the Company. The Company had $ 140,533 and $ 198,392 in operating lease expenses for the years ended October 31, 2025 and October 31, 2024, respectively. F- 22 Note 9 – Income Tax The Company is subject to federal income taxes and state income tax in the U.S. Significant judgment is required in determining the provision for income taxes and income tax assets and liabilities, including evaluating uncertainties in the application of accounting principles and complex tax laws. The Tax Cuts and Jobs Act (the “Tax Act”) was enacted on December 22, 2017 and reduced the U.S. federal corporate tax rate from 35 % to 21 %, eliminated corporate Alternative Minimum Tax, modified rules for expensing capital investment, and limited the deduction of interest expense for certain companies. The Company fulfilled and shipped all the Products from Florida and, thus, it is subject to the state corporate income tax of Florida with a tax rate of 5.5 %. There is no difference between the income tax computed at the combined federal and state statutory rate to the income tax effective rate. Significant components of the tax (benefit) expense recognized in the accompanying statements of operations for the years ended October 31, 2025, and October 31, 2024, are as follows: Schedule of components of income tax expense October 31, 2025 2024 Current Tax Expense: Federal $ — $ — State ( 18,942 ) 19,658 Total Current Tax Expense ( 18,942 ) 19,658 Deferred Tax Expense: Federal — — State — — Total Deferred Tax Expense — — Tax provision: Federal — — State ( 18,942 ) 19,658 Total $ ( 18,942 ) $ 19,658 Total net deferred taxes are comprised of the following on October 31, 2025, and October 31, 2024: Schedule of deferred tax assets and liabilities October 31, 2025 2024 Deferred Tax Assets: Stock Compensation Expense – NQSO $ 183,640 $ 1,871,908 Other 2,735,650 837,264 Net Operating Loss Carryforwards 7,186,210 6,258,699 Total Deferred Tax Asset 10,105,500 8,967,871 Deferred Tax Liabilities: Prepaid Expenses ( 3,401 ) ( 75,319 ) Right of Use Asset — ( 188,810 ) Total Deferred Tax Liabilities ( 3,401 ) ( 264,129 ) Less: Valuation Allowance ( 10,102,099 ) ( 8,703,742 ) Net Deferred Tax Asset $ — $ — F- 23 The Company has Federal NOL carryforwards of approximately $ 34.2 million and state NOL carryforwards of approximately $ 0.4 million. With the changes instituted by the CARES Act, the Federal NOLs have an indefinite life and will not expire. The Company’s federal and state tax returns for the 2023 and 2024 tax years generally remain subject to examination by U.S. and various state authorities. A valuation allowance is recorded to reduce the deferred tax asset if, based on the weight of the evidence, it is more likely than not that some portion or all the deferred tax assets will not be realized. After consideration of all the evidence, both positive and negative, management has determined that a valuation allowance of $ 10,102,099 for the year ended on October 31, 2025, it is necessary to reduce the deferred tax asset to the amount that will more likely than not be realized. Note 10 – Commitments and Contingencies The Company follows ASC 450-20, Los s Contingencies, to report accounting for contingencies. Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. There were no commitments or contingencies as of October 31, 2025, and October 31, 2024, other than the below: QuikfillRx Service Agreement On March 31, 2020, the Company entered into a service agreement (the “Service Agreement”) with QuikfillRx LLC, a Florida limited liability company (“QuikfillRx”), whereby QuikfillRx provides the Company with certain services and support relating to sales management, website development and design, graphics, content, public communication, social media, management and analytics, and market and other research (collectively, the “Services”). Effective as of November 9, 2022, the Company entered into its latest amendment to the Service Agreement with QuikfillRx (collectively with prior amendments, the “Amended Service Agreement”). The November 9, 2022 amendment to the Service Agreement was captioned as the “Fourth Amendment” although it was the fifth amendment to the Service Agreement. Pursuant to the Amended Service Agreement: (a) the term of the Amended Service Agreement was extended (unless earlier terminated pursuant to the terms of the Amended Service Agreement) from November 1, 2022 (the “Effective Date”) until October 31, 2025, following which the term shall automatically renew for successive one (1) year period beginning November 1, 2025; (b) QuikfillRx agreed to change its “doing business as” name to “Kaival Marketing Services” within thirty (30) days following the Effective Date; (c) it was provided that either party may terminate the Amended Service Agreement without cause upon not less than ninety (90) days prior written notice to the other party; (d) QuikfillRx was granted a one-time, fully vested, ten-year non-qualified option award to purchase up to 11,905 shares of Company common stock with an exercise price of $20.72 per share (the closing price of the Company’s common stock on November 9, 2022). The option grant was memorialized pursuant to a Nonqualified Option Agreement, dated November 9, 2022, between the Company and QuikfillRx; and (e) the parties agreed to revise the compensation for services as follows: (i) payment of $125,000 per month; (ii) bonus equivalent to 0.27% of the applicable gross quarterly sales and (iii) a grant of 3,000,000 nonqualified stock options to purchase shares of Company common stock which shall vest based on achievement of certain net revenue and profit margin targets up to $180,000,000 in total net revenues over a period of 3 years. On February 21, 2024, the Company terminated the agreement and all amendments with QuikFillRx. Per the termination, the Company was required to pay $ 80,000 by March 1, 2024, in full satisfaction of all obligations, debts, and prior services, including but not limited to stock incentives, bonuses, third party obligations, owed by the Company to QuickfillRx. The Company made the required payment on February 28, 2024. F- 24 International Trade Commission claims against the Company On June 11, 2024, RAI Strategic Holdings, Inc., R.J. Reynolds Vapor Company, R.J. Reynolds Tobacco Company, and RAI Services Company (collectively, the “RJ Reynolds Entities”) filed a patent infringement complaint with the International Trade Commission (the “ITC”) against Bidi, the Company, and forty (40) other respondents (the “ITC Complaint”) pursuant to Section 337 of the Tariff Act of 1930, as amended. Specifically, the ITC Complaint alleges that one or more components or elements of the Bidi Stick infringe U.S. Patent No. 11,925,202, which is owned by one of the RJ Reynolds Entities. The ITC Complaint requests the ITC grant: (a) temporary and permanent limited exclusion orders pursuant to Section 337(e) of the Tariff Act of 1930, as amended, which would prohibit the importation of the Bidi Stick in the United States; and (b) issue temporary and permanent cease and desist orders pursuant to 337(f) of the Tariff Act of 1930, as amended, which would prohibit the sale and distribution of the Bidi Stick in the United States. On July 17, 2024, the Company was dismissed from the ITC proceeding and is no longer a defendant in the ITC proceeding. No damages are recoverable in the proceedings before the ITC. If Bidi is prohibited from importing the Bidi Stick, then the Company’s business, operations, financial results, and reputation would be significantly adversely impacted. Note 11 – Subsequent Events During December 2025, the Company issued 4,892,000 shares of common stock through its ATM offering raising $ 1,111,858 and paid fees and expenses of $ 96,415 to Maxim for net proceeds of $ 1,015,443 . During December 2025, the Company canceled 2,950,000 shares of common stock issued to the Directors and Officers of the Company in January 2025 in relation to the terminated merger agreement with Delta. The Company’s stock was delisted from the Nasdaq Stock Market on December 23 , 2025 and is currently trading on the OTC Pink Limit Market. F- 25 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure. None.